Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

19.18 -0.40 (-2.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Arcturus Therapeutics Shares Are Moving Higher After Hours
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares are booming in Tuesday's after-hours session after the company reported fourth-quarter results and provided an update on  
Via Benzinga
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
A Preview Of Arcturus Therapeutics's Earnings
Via Benzinga
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics's Return On Capital Employed Overview
Via Benzinga
Why Arcturus Therapeutics Stock Is Skyrocketing Today
Investors are applauding Arcturus' collaboration with CSL. 
Via The Motley Fool
Where Arcturus Therapeutics Stands With Analysts
Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
Via Benzinga
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at the Following Investor Conferences in November
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
Why Is Rogers Corporation (ROG) Stock Down 44% Today?
Rogers Corporation (ROG) stock is falling hard on Wednesday following confirmation that DuPont (DD) no longer plans to acquire the company. 
Via InvestorPlace
Why Is Benefitfocus (BNFT) Stock Up 48% Today?
Benefitfocus (BNFT) stock is rocketing higher on Wednesday as investors react to a $570 million acquisition deal with Voya Financial (VOYA). 
Via InvestorPlace
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
What 4 Analyst Ratings Have To Say About Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket
Gainers Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! 
Via InvestorPlace
Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.